EUVIMEDOdkrijte EUVIMED
Crossref

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection

Yu-Ping Chang, Ji-Yuh Lee, Chi-Yi Chen, Wei-Yu Kao, Chih-Lin Lin, Sheng-Shun Yang, Yu-Lueng Shih, Cheng-Yuan Peng iD, Fu-Jen Lee, Ming-Chang Tsai, Shang-Chin Huang, Tung-Hung Su iD and 5 more

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70029 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2025. Written by Yu-Ping Chang and 16 co-authors. Institution: Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Prediabetic State, Antiviral Agents, Hepatitis C, Chronic. Cited 13 times so far (Crossref); 45 references. Funded by: National Taiwan University Hospital.

PovzetekSubjectsBibliografski podatkiCiteRelated studies

Abstract (original language)

Background

Data regarding the risk of incident type 2 diabetes (T2D) and prediabetes among patients with hepatitis C virus (HCV) achieving direct‐acting antivirals (DAAs)‐induced sustained virologic response (SVR 12 ) remains limited.

Methods

A total of 1079 patients, including 589 with normoglycemia and 490 with prediabetes, who underwent biannual fasting glucose and glycosylated haemoglobin (HbA1c) assessment for a median post‐SVR 12 follow‐up of 5.5 years, were enrolled. We reported the crude (cIRs) and age‐standardised incidence rates (ASIRs) of T2D and prediabetes. Factors associated with incident T2D and prediabetes were assessed using the Cox proportional hazards models.

Results

The cIRs of T2D and prediabetes were 1.18 and 8.99 per 100 person‐years of follow‐up (PYFU), respectively. Additionally, the ASIRs of T2D and prediabetes were 1.09 (95% CI: 0.76–1.53) and 8.47 (95% CI: 7.23–9.90) per 100 PYFU. Prediabetes (adjusted hazard ratio [aHR]: 4.71; 95% confidence interval (CI): 2.55–8.70, p < 0.001), body mass index (BMI) per kg/m 2 increase (aHR: 1.17; 95% CI: 1.09–1.26, p < 0.001) and liver stiffness measurement (LSM) per kPa increase (aHR: 1.05; 95% CI: 1.02–1.09, p = 0.001) were associated with a higher risk of incident T2D. Age per year increase (aHR: 1.02; 95% CI: 1.01–1.03, p < 0.001) was associated with a higher risk of incident prediabetes.

Conclusion

The incidence rates of T2D and prediabetes remain substantial among patients after HCV eradication. Lifestyle modification, drug therapy and regular monitoring of glycemic status are crucial for patients at risk of developing T2D and prediabetes following HCV clearance.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2Prediabetic StateAntiviral AgentsHepatitis C, ChronicHepatitis CHumansMaleFemaleMiddle AgedIncidenceRisk FactorsAgedAdultSustained Virologic ResponseGlycated HemoglobinBlood GlucoseProportional Hazards Models

Author keywords

direct‐acting antiviralhepatitis C virusprediabetessustained virologic responsetype 2 diabetes

Substances

Antiviral AgentsGlycated HemoglobinBlood Glucose

Authors and institutions

  • Department of Internal Medicine, National Taiwan University Biomedical Park Hospital, Hsin-Chu, Taiwan.
  • Department of Internal Medicine, National Taiwan University Hospital, Yunlin, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
  • Graduate Institute of Metabolism and Obesity Sciences, Taipei Medical University, Taipei, Taiwan.

ORCID profiles: Cheng-Yuan Peng, Tung-Hung Su, Chun-Jen Liu, Jia-Horng Kao, Chen-Hua Liu

Funding

  • National Taiwan University Hospital

Cite

APA

Chang, Y. P., Lee, J. Y., Chen, C. Y., Kao, W. Y., Lin, C. L., Yang, S. S., Shih, Y. L., Peng, C. Y., Lee, F. J., Tsai, M. C., Huang, S. C., Su, T. H., Tseng, T. C., Liu, C. J., Chen, P. J., Kao, J. H., & Liu, C. H. (2025). Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70029

Vancouver

Chang YP, Lee JY, Chen CY, Kao WY, Lin CL, Yang SS, et al. Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70029

BibTeX
@article{Chang2025,
  author = {Chang, Yu-Ping and Lee, Ji-Yuh and Chen, Chi-Yi and Kao, Wei-Yu and Lin, Chih-Lin and Yang, Sheng-Shun and Shih, Yu-Lueng and Peng, Cheng-Yuan and Lee, Fu-Jen and Tsai, Ming-Chang and Huang, Shang-Chin and Su, Tung-Hung and Tseng, Tai-Chung and Liu, Chun-Jen and Chen, Pei-Jer and Kao, Jia-Horng and Liu, Chen-Hua},
  title = {Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70029}
}
Start for free →